Carbahal Olsen Financial Services Group LLC Sells 460 Shares of Gilead Sciences, Inc. $GILD

Carbahal Olsen Financial Services Group LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 13.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 2,975 shares of the biopharmaceutical company’s stock after selling 460 shares during the period. Gilead Sciences comprises about 0.3% of Carbahal Olsen Financial Services Group LLC’s investment portfolio, making the stock its 25th largest position. Carbahal Olsen Financial Services Group LLC’s holdings in Gilead Sciences were worth $330,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC bought a new stake in shares of Gilead Sciences in the 1st quarter valued at about $25,000. Activest Wealth Management grew its position in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the last quarter. Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences in the 1st quarter valued at about $29,000. Colonial Trust Advisors grew its position in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 213 shares during the last quarter. Finally, Core Alternative Capital lifted its stake in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 241 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.4%

GILD stock opened at $117.18 on Monday. The stock’s 50 day simple moving average is $114.65 and its 200 day simple moving average is $110.25. Gilead Sciences, Inc. has a fifty-two week low of $84.17 and a fifty-two week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a market cap of $145.40 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the prior year, the business earned $2.01 EPS. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is currently 62.95%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on GILD. Rothschild & Co Redburn boosted their price objective on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Finally, JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $118.08.

Get Our Latest Stock Report on Gilead Sciences

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the sale, the insider directly owned 113,193 shares of the company’s stock, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares of the company’s stock, valued at $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 77,000 shares of company stock valued at $8,853,430. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Further Reading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.